This whitepaper explores:

1. Why hMSCs embody a key foundational technology platform, providing a robust vehicle for widespread translational development across regenerative medicine applications
2. How cell manufacturing science and its wave of process innovation is absolutely required to accompany any prior wave of cell therapy product innovation
3. Where hMSC bioproduction scale-up fits on a technology roadmap to fill research, clinical, and commercial needs for our RegenMed industry, together with NIST and our collaborators in the National Cell Manufacturing Consortium
4. Which specific milestones of bioprocess economics are being achieved, how they will contribute to consumer-benefiting economies of scale
5. What is new strategy to leverage for hMSCs in the world of cell therapies, previously pioneered analogously by protein biologics manufacturers
6. When we can experience the boost that these efforts will contribute to the whole of biomanufacturing